Schedule 13G ownership disclosure

XILIO THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 98422T100

Event date: 2025-02-11

Filing-level shares
4,347,826.00
Percent of class
9.0%
  • AbbVie Inc.

    Shares: 4,347,826.00 · Class: 9.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-014772
Form type
SCHEDULE 13G
Filer
AbbVie Inc.
CIK
CIK 1551152
Filed
Feb 18, 2025
Reporting period
Feb 11, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub